Sanofi Puts Up $125M to Partner on Oral Drug That Could Be Dupixent's Successor
Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent.
Source: medcitynews.com